Alexander Norman

Alexander Norman

Auto-generated profile, based on publicly available information

Alexander Norman

School of Chemistry and Australian Research Council Centre of Excellence for Innovations in Peptide and Protein Science The University of Sydney Sydney NSW 2006 Australia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
TBTara K. Bartolec
Tara K. Bartolec
XVXabier Vázquez-Campos
Xabier Vázquez-Campos
ANAlexander Norman
Alexander Norman
CLClement Luong
Clement Luong
MJMarcus Johnson
Marcus Johnson
JLJason K. K. Low
Jason K. K. Low
Significant recent advances in structural biology, particularly in the field of cryoelectron microscopy, have dramatically expanded our ability to create structural models of proteins and protein complexes. However, many proteins remain refractory to these approaches because of their low abundance, low stability, or—in the case of complexes—simply not having yet been analyzed. Here, we demonstrate the power of using cross-linking mass spectrometry (XL-MS) for the high-throughput experimental assessment of the structures of proteins and protein complexes. This included those produced by high-resolution but in vitro experimental data, as well as in silico predictions based on amino acid sequence alone. We present the largest XL-MS dataset to date, describing 28,910 unique residue pairs captured across 4,084 unique human proteins and 2,110 unique protein–protein interactions. We show that models of proteins and their complexes predicted by AlphaFold2, and inspired and corroborated by the XL-MS data, offer opportunities to deeply mine the structural proteome and interactome and reveal mechanisms underlying protein structure and function.

9 March 2022 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
SKSameer S. Kulkarni
Sameer S. Kulkarni
EWEmma Elizabeth Watson
Emma Elizabeth Watson
JMJoshua W. C. Maxwell
Joshua W. C. Maxwell
GNGerhard Niederacher
Gerhard Niederacher
JJJason Johansen‐Leete
Jason Johansen‐Leete
RPRichard J. Payne
Richard J. Payne
Herein, we describe the development and application of a novel expressed protein selenoester ligation (EPSL) methodology for the one‐pot semi‐synthesis of modified proteins. EPSL harnesses the rapid kinetics of ligation reactions between modified synthetic selenopeptides and protein aryl selenoesters (generated from expressed intein fusion precursors) followed by in situ chemoselective deselenization to afford target proteins at concentrations that preclude the use of traditional ligation methods. The utility of the EPSL technology is showcased through the efficient semi‐synthesis of ubiquitinated polypeptides, lipidated analogues of the membrane‐associated GTPase YPT6, and site‐specifically phosphorylated variants of the oligomeric chaperone protein Hsp27 at high dilution.

20 June 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
VTVito Thijssen
Vito Thijssen
DHDaniel Hurdiss
Daniel Hurdiss
ODOliver J. Debski-Antoniak
Oliver J. Debski-Antoniak
MSMatthew A. Spence
Matthew A. Spence
CFCharlotte Franck
Charlotte Franck
SJSeino Jongkees
Seino Jongkees
The ongoing COVID-19 pandemic has had great societal and health consequences. Despite the availability of vaccines, infection rates remain high due to immune evasive Omicron sublineages. Broad-spectrum antivirals are needed to safeguard against emerging variants and future pandemics. We used messenger RNA (mRNA) display under a reprogrammed genetic code to find a spike-targeting macrocyclic peptide that inhibits SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) Wuhan strain infection and pseudoviruses containing spike proteins of SARS-CoV-2 variants or related sarbecoviruses. Structural and bioinformatic analyses reveal a conserved binding pocket between the receptor-binding domain, N-terminal domain, and S2 region, distal to the angiotensin-converting enzyme 2 receptor–interaction site. Our data reveal a hitherto unexplored site of vulnerability in sarbecoviruses that peptides and potentially other drug-like molecules can target.

9 March 2022 in Angewandte Chemie
Verified
Journal Article
Open access
SKSameer S. Kulkarni
Sameer S. Kulkarni
EWEmma Elizabeth Watson
Emma Elizabeth Watson
JMJoshua W. C. Maxwell
Joshua W. C. Maxwell
GNGerhard Niederacher
Gerhard Niederacher
JJJason Johansen‐Leete
Jason Johansen‐Leete
RPRichard J. Payne
Richard J. Payne
Herein, we describe the development and application of a novel expressed protein selenoester ligation (EPSL) methodology for the one‐pot semi‐synthesis of modified proteins. EPSL harnesses the rapid kinetics of ligation reactions between modified synthetic selenopeptides and protein aryl selenoesters (generated from expressed intein fusion precursors) followed by in situ chemoselective deselenization to afford target proteins at concentrations that preclude the use of traditional ligation methods. The utility of the EPSL technology is showcased through the efficient semi‐synthesis of ubiquitinated polypeptides, lipidated analogues of the membrane‐associated GTPase YPT6, and site‐specifically phosphorylated variants of the oligomeric chaperone protein Hsp27 at high dilution.

16 November 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
TBTara K. Bartolec
Tara K. Bartolec
XVXabier Vázquez-Campos
Xabier Vázquez-Campos
ANAlexander Norman
Alexander Norman
CLClement Luong
Clement Luong
RPRichard J. Payne
Richard J. Payne
JLJason K. K. Low
Jason K. K. Low
Significant recent advances in structural biology, particularly in the field of cryo-electron microscopy, have dramatically expanded our ability to create structural models of proteins and protein complexes. However, many proteins remain refractory to these approaches because of their low abundance, low stability or – in the case of complexes – simply not having yet been analysed. Here, we demonstrate the power of combining cross-linking mass spectrometry (XL-MS) with artificial intelligence-based structure prediction to discover and experimentally substantiate models for protein and protein complex structures at proteome scale. We present the deepest XL-MS dataset to date, describing 28,910 unique residue pairs captured across 4,084 unique human proteins and 2,110 unique protein-protein interactions. We show that integrative models of complexes driven by AlphaFold Multimer and inspired and corroborated by the XL-MS data offer new opportunities to deeply mine the structural proteome and interactome and reveal new mechanisms underlying protein structure and function.

11 November 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
VTVito Thijssen
Vito Thijssen
DHDaniel Hurdiss
Daniel Hurdiss
ODOliver J. Debski-Antoniak
Oliver J. Debski-Antoniak
MSMatthew A. Spence
Matthew A. Spence
CFCharlotte Franck
Charlotte Franck
SJSeino Jongkees
Seino Jongkees
The ongoing COVID-19 pandemic has had great societal and health consequences. Despite the availability of vaccines, infection rates remain high due to immune evasive Omicron sublineages. Broad-spectrum antivirals are needed to safeguard against emerging variants and future pandemics. We used mRNA display under a reprogrammed genetic code to find a spike-targeting macrocyclic peptide that inhibits SARS-CoV-2 Wuhan strain infection and also pseudoviruses containing spike proteins of SARS-CoV-2 variants or related sarbecoviruses. Structural and bioinformatic analyses reveal a conserved binding pocket between the receptor binding domain and other domains, distal to the ACE2 receptor-interaction site. Collectively, our data reveal a hitherto unexplored site of vulnerability in sarbecoviruses that can be targeted by peptides and potentially other drug-like molecules. One-Sentence Summary We identify a conserved site on the SARS-CoV-2 spike that can be targeted by a broadly neutralizing macrocyclic peptide.